BioSpace News Archive

J&J Cuts R&D at Netherlands Infectious Disease, Vaccine Unit

After slimming down its infectious diseases and vaccines business, Johnson & Johnson now appears to be ending research and development at a Dutch-based unit, except for a few programs.

August 24, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors

Data suggests divarasib could be more potent than already approved KRAS inhibitors from Amgen and Mirati, but the study’s authors caution against cross-trial comparisons.

August 24, 2023
·
2 min read
·
Kate Goodwin
Novo Nordisk Taps Thermo Fisher to Help Meet Wegovy Demand: Reuters

The Danish drugmaker is leveraging Thermo Fisher Scientific as Wegovy demand surges and amid production problems with manufacturer Catalent, Reuters reported on Wednesday.

August 24, 2023
·
1 min read
·
Connor Lynch
Promising Vertex Pain Med Points to New Era for Analgesics

While some biopharma companies seek an effective and non-addictive alternative to opioids, others are looking to make opioids themselves safer.

August 24, 2023
·
6 min read
·
Jill Neimark
Opinion: Neuroactive Steroids Face Hurdles on the Path to Bigger Markets

As the FDA’s recent rejection of Biogen and Sage’s zuranolone for major depressive disorder highlights, biopharma companies will need to tackle emerging challenges to bring more of these drugs to patients.

August 24, 2023
·
3 min read
·
Jia Jie Chen
Business

CVS Health Enters Biosimilars Market with Launch of Cordavis Subsidiary

The consumer healthcare brand is joining the growing biosimilars market in the U.S. with its new subsidiary Cordavis, which will market a Humira biosimilar as its first product.

August 24, 2023
·
2 min read
·
Tristan Manalac
AbbVie Removes Two Early-Stage Cancer Assets from Pipeline

The company appears to be terminating the development of two Phase I antibody-drug conjugates in cancer, ABBV-011 and the Pfizer-partnered ABBV-647.

August 24, 2023
·
2 min read
·
Tristan Manalac
FDA

FDA Action Alert: BMS, Outlook and BiolineRx

In the next two weeks, the FDA will hand out regulatory verdicts to BMS, Outlook Therapeutics and BioLineRx.

August 24, 2023
·
4 min read
·
Tristan Manalac
Business

Royalty Pharma to Pay Potential $500M for Royalties on Ferring’s Gene Therapy

The world’s largest buyer of biopharma royalties is paying $300 million up front and $200 million in milestone payments for Ferring Pharmaceuticals’ FDA-approved bladder cancer drug Adstiladrin.

August 24, 2023
·
2 min read
·
Connor Lynch
Policy

European Medicines Agency Accepts Novaliq’s Marketing Authorization Application for CyclASol® (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease

Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the European Medicines Agency has accepted the marketing authorization application for CyclASol for regulatory review.

August 24, 2023
·
3 min read